AstraZeneca Joins Rival to Develop New TB Treatment
March 15, 2011
The newly formed More Medicines for Tuberculosis (MM4TB) consortium aims to develop more effective and shorter-course TB treatments for the global marketplace.
MM4TB is being funded by a €16 million (US $22.3 million) European Union grant. The effort joins drug maker AstraZeneca and French rival Sanofi-Aventis; the Ecole Polytechnique Federale de Lausanne; the universities of Cambridge, Pavia (Italy) and Uppsala (Sweden); and other entities. It will be led by EPFL professor Stuart Cole, a TB expert.
The Guardian (London)
03.03.2011; Julia Kollewe
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)